<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jah39286" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="pmc-domain-id">1888</journal-id><journal-id journal-id-type="pmc-domain">jaha</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11010083</article-id><article-id pub-id-type="pmcid-ver">PMC11010083.1</article-id><article-id pub-id-type="pmcaid">11010083</article-id><article-id pub-id-type="pmcaiid">11010083</article-id><article-id pub-id-type="pmid">38348779</article-id><article-id pub-id-type="doi">10.1161/JAHA.122.026921</article-id><article-id pub-id-type="publisher-id">JAH39286</article-id><article-id pub-id-type="other">JAHA/2022/026921-T</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease</article-title><alt-title alt-title-type="right-running-head">Age and Aspirin Dosing in Secondary Prevention</alt-title><alt-title alt-title-type="left-running-head">Marquis&#8208;Gravel et&#160;al</alt-title></title-group><contrib-group><contrib id="jah39286-cr-0001" contrib-type="author"><name name-style="western"><surname>Marquis&#8208;Gravel</surname><given-names initials="G">Guillaume</given-names></name><degrees>MD, MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2965-1504</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah39286-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah39286-cr-0002" contrib-type="author"><name name-style="western"><surname>Stebbins</surname><given-names initials="A">Amanda</given-names></name><degrees>MS</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0808-9025</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah39286-cr-0003" contrib-type="author"><name name-style="western"><surname>Wruck</surname><given-names initials="LM">Lisa M.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1732-9067</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah39286-cr-0004" contrib-type="author"><name name-style="western"><surname>Roe</surname><given-names initials="MT">Matthew T.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4049-3458</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah39286-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah39286-cr-0005" contrib-type="author"><name name-style="western"><surname>Effron</surname><given-names initials="MB">Mark B.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4050-5030</contrib-id><xref rid="jah39286-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jah39286-cr-0006" contrib-type="author"><name name-style="western"><surname>Hammill</surname><given-names initials="BG">Bradley G.</given-names></name><degrees>DrPH</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0389-6434</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah39286-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="jah39286-cr-0007" contrib-type="author"><name name-style="western"><surname>Whittle</surname><given-names initials="J">Jeff</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9544-838X</contrib-id><xref rid="jah39286-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="jah39286-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="jah39286-cr-0008" contrib-type="author"><name name-style="western"><surname>VanWormer</surname><given-names initials="JJ">Jeffrey J.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8733-8703</contrib-id><xref rid="jah39286-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="jah39286-cr-0009" contrib-type="author"><name name-style="western"><surname>Robertson</surname><given-names initials="HR">Holly R.</given-names></name><degrees>PhD</degrees><xref rid="jah39286-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="jah39286-cr-0010" contrib-type="author"><name name-style="western"><surname>Alikhaani</surname><given-names initials="JD">Jacqueline D.</given-names></name><degrees>BA</degrees><xref rid="jah39286-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="jah39286-cr-0011" contrib-type="author"><name name-style="western"><surname>Kripalani</surname><given-names initials="S">Sunil</given-names></name><degrees>MD</degrees><xref rid="jah39286-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="jah39286-cr-0012" contrib-type="author"><name name-style="western"><surname>Farrehi</surname><given-names initials="PM">Peter M.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1576-7557</contrib-id><xref rid="jah39286-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="jah39286-cr-0013" contrib-type="author"><name name-style="western"><surname>Girotra</surname><given-names initials="S">Saket</given-names></name><degrees>MD, SM</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4784-4513</contrib-id><xref rid="jah39286-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="jah39286-cr-0014" contrib-type="author"><name name-style="western"><surname>Benziger</surname><given-names initials="CP">Catherine P.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8992-6197</contrib-id><xref rid="jah39286-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="jah39286-cr-0015" contrib-type="author"><name name-style="western"><surname>Polonsky</surname><given-names initials="TS">Tamar S.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2112-9244</contrib-id><xref rid="jah39286-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="jah39286-cr-0016" contrib-type="author"><name name-style="western"><surname>Merritt</surname><given-names initials="JG">J. Greg</given-names></name><degrees>PhD</degrees><xref rid="jah39286-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="jah39286-cr-0017" contrib-type="author"><name name-style="western"><surname>Gupta</surname><given-names initials="K">Kamal</given-names></name><degrees>MBBS, MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2440-9033</contrib-id><xref rid="jah39286-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="jah39286-cr-0018" contrib-type="author"><name name-style="western"><surname>McCormick</surname><given-names initials="TE">Thomas E.</given-names><suffix>III</suffix></name><degrees>MS</degrees><xref rid="jah39286-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="jah39286-cr-0019" contrib-type="author"><name name-style="western"><surname>Knowlton</surname><given-names initials="KU">Kirk U.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3544-4130</contrib-id><xref rid="jah39286-aff-0019" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib id="jah39286-cr-0020" contrib-type="author"><name name-style="western"><surname>Jain</surname><given-names initials="SK">Sandeep K.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5815-370X</contrib-id><xref rid="jah39286-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="jah39286-cr-0021" contrib-type="author"><name name-style="western"><surname>Kochar</surname><given-names initials="A">Ajar</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3570-2136</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah39286-cr-0022" contrib-type="author"><name name-style="western"><surname>Rothman</surname><given-names initials="RL">Russell L.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1506-3990</contrib-id><xref rid="jah39286-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="jah39286-cr-0023" contrib-type="author"><name name-style="western"><surname>Harrington</surname><given-names initials="RA">Robert A.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5450-8676</contrib-id><xref rid="jah39286-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="jah39286-cr-0024" contrib-type="author"><name name-style="western"><surname>Hernandez</surname><given-names initials="AF">Adrian F.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3387-9616</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah39286-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah39286-cr-0025" contrib-type="author" corresp="yes"><name name-style="western"><surname>Jones</surname><given-names initials="WS">W. Schuyler</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7288-9596</contrib-id><xref rid="jah39286-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah39286-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>schuyler.jones@duke.edu</email></address></contrib></contrib-group><aff id="jah39286-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Duke Clinical Research Institute</institution>
<city>Durham</city>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah39286-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Montreal Heart Institute, Universit&#233; de Montr&#233;al</institution>
<named-content content-type="country-part">QC</named-content>
<country country="CA">Canada</country>
</aff><aff id="jah39286-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Duke University Medical Center</institution>
<city>Durham</city>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah39286-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Ochsner Clinical School, John Ochsner Heart and Vascular Institute, University of Queensland School of Medicine</institution>
<city>New Orleans</city>
<named-content content-type="country-part">LA</named-content>
</aff><aff id="jah39286-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Population Health Sciences</named-content>
<institution>Duke School of Medicine</institution>
<city>Durham</city>
<named-content content-type="country-part">NC</named-content>
</aff><aff id="jah39286-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine, Division of General Internal Medicine</named-content>
<institution>Medical College of Wisconsin</institution>
<city>Milwaukee</city>
<named-content content-type="country-part">WI</named-content>
</aff><aff id="jah39286-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Center for Advancing Population Science, Medical College of Wisconsin</institution>
<city>Milwaukee</city>
<named-content content-type="country-part">WI</named-content>
</aff><aff id="jah39286-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>Marshfield Clinic Research Institute</institution>
<city>Marshfield</city>
<named-content content-type="country-part">WI</named-content>
</aff><aff id="jah39286-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>Medidata, A Dassault Syst&#232;mes Company</institution>
<city>New York</city>
<named-content content-type="country-part">NY</named-content>
</aff><aff id="jah39286-aff-0010">
<label>
<sup>10</sup>
</label>
<institution>pSCANNER, University of California in Los Angeles Center</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">CA</named-content>
</aff><aff id="jah39286-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Vanderbilt Institute for Medicine and Public Health</named-content>
<institution>Vanderbilt University Medical Center</institution>
<city>Nashville</city>
<named-content content-type="country-part">TN</named-content>
</aff><aff id="jah39286-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Division of Cardiovascular Medicine</named-content>
<institution>University of Michigan</institution>
<city>Ann Arbor</city>
<named-content content-type="country-part">MI</named-content>
</aff><aff id="jah39286-aff-0013">
<label>
<sup>13</sup>
</label>
<institution>University of Iowa Carver College of Medicine and Comprehensive Access and Delivery Research and Evaluation, Iowa City Veterans Affairs Medical Center</institution>
<city>Iowa City</city>
<named-content content-type="country-part">IA</named-content>
</aff><aff id="jah39286-aff-0014">
<label>
<sup>14</sup>
</label>
<institution>Essentia Health</institution>
<city>Duluth</city>
<named-content content-type="country-part">MN</named-content>
</aff><aff id="jah39286-aff-0015">
<label>
<sup>15</sup>
</label>
<institution>University of Chicago</institution>
<named-content content-type="country-part">IL</named-content>
</aff><aff id="jah39286-aff-0016">
<label>
<sup>16</sup>
</label>
<institution>Patient&#8208;Centered Network of Learning Health Systems (LHSNet)</institution>
<city>Ann Arbor</city>
<named-content content-type="country-part">MI</named-content>
</aff><aff id="jah39286-aff-0017">
<label>
<sup>17</sup>
</label>
<institution>University of Kansas Medical Center and Hospital</institution>
<named-content content-type="country-part">KS</named-content>
</aff><aff id="jah39286-aff-0018">
<label>
<sup>18</sup>
</label>
<institution>Johns Hopkins Medical Center</institution>
<city>Baltimore</city>
<named-content content-type="country-part">MD</named-content>
</aff><aff id="jah39286-aff-0019">
<label>
<sup>19</sup>
</label>
<institution>Intermountain Medical Center</institution>
<city>Salt Lake City</city>
<named-content content-type="country-part">UT</named-content>
</aff><aff id="jah39286-aff-0020">
<label>
<sup>20</sup>
</label>
<institution>University of Pittsburgh School of Medicine, UPMC Heart and Vascular Institute</institution>
<city>Pittsburgh</city>
<named-content content-type="country-part">PA</named-content>
</aff><aff id="jah39286-aff-0021">
<label>
<sup>21</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Stanford University</institution>
<city>Stanford</city>
<named-content content-type="country-part">CA</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence to: W. Schuyler Jones, MD, Duke University Medical Center, PO Box&#160;3126, DUMC, Durham, NC 27710. Email: <email>schuyler.jones@duke.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>20</day><month>2</month><year>2024</year></pub-date><volume>13</volume><issue seq="80">4</issue><issue-id pub-id-type="pmc-issue-id">459900</issue-id><issue-id pub-id-type="doi">10.1002/jah3.v13.4</issue-id><elocation-id>e026921</elocation-id><history><date date-type="received"><day>13</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>04</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>02</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-24 17:25:13.990"><day>24</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JAH3-13-e026921.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JAH3-13-e026921.pdf"/><abstract><sec id="jah39286-sec-0001"><title>Background</title><p>In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to age in atherosclerotic cardiovascular disease.</p></sec><sec id="jah39286-sec-0002"><title>Methods and Results</title><p>In the ADAPTABLE (Aspirin Dosing: A Patient&#8208;Centric Trial Assessing Benefits and Long&#8208;Term Effectiveness) trial, patients with atherosclerotic cardiovascular disease were randomized to daily aspirin doses of 81&#8201;mg or 325&#8201;mg. The primary effectiveness end point was death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke. The primary safety end point was hospitalization for bleeding requiring transfusion. A total of 15&#8201;076 participants were randomized to aspirin 81&#8201;mg (n=7540) or 325&#8201;mg (n=7536) daily (median follow&#8208;up: 26.2&#8201;months; interquartile range: 19.0&#8211;34.9&#8201;months). Median age was 67.6&#8201;years (interquartile range: 60.7&#8211;73.6&#8201;years). Among participants aged &lt;65&#8201;years (n=5841 [38.7%]), a primary end point occurred in 226 (7.54%) in the 81 mg group, and in 191 (6.80%) in the 325 mg group (adjusted hazard ratio [HR], 1.23 [95% CI, 1.01&#8211;1.49]). Among participants aged &#8805;65&#8201;years (n=9235 [61.3%]), a primary end point occurred in 364 (7.12%) in the 81 mg group, and in 378 (7.96%) in the 325 mg group (adjusted HR, 0.95 [95% CI, 0.82&#8211;1.10]). The age&#8211;dose interaction was not significant (<italic toggle="no">P</italic>=0.559). There was no significant interaction between age and the randomized aspirin dose for the secondary effectiveness and the primary safety bleeding end points (<italic toggle="no">P</italic>&gt;0.05 for all).</p></sec><sec id="jah39286-sec-0003"><title>Conclusions</title><p>Age does not modify the impact of aspirin dosing (81&#8201;mg or 325&#8201;mg daily) on clinical end points in secondary prevention of atherosclerotic cardiovascular disease.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah39286-kwd-0001">acetylsalicylic acid</kwd><kwd id="jah39286-kwd-0002">age</kwd><kwd id="jah39286-kwd-0003">aspirin</kwd><kwd id="jah39286-kwd-0004">atherosclerotic cardiovascular disease</kwd><kwd id="jah39286-kwd-0005">coronary artery disease</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Vascular Disease</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Patient&#8208;Centered Outcomes Research Institute</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="4"/><page-count count="9"/><word-count count="6316"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>20 February 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.8 mode:remove_FC converted:19.02.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jah39286-ntgp-0001"><fn id="jah39286-note-0001"><p>This article was sent to Daniel Edmundowicz, MD, Guest Editor, for review by expert referees, editorial decision, and final disposition.</p></fn><fn id="jah39286-note-0002"><p>Supplemental Material is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.026921" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.026921</ext-link>
</p></fn><fn id="jah39286-note-0003"><p>For Sources of Funding and Disclosures, see page 8.</p></fn></fn-group></notes></front><body id="jah39286-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="jah39286-blkfxd-0001" orientation="portrait"><caption><title>Clinical Perspective</title></caption><sec id="jah39286-sec-0006"><title>What Is New?</title><p>
<list list-type="bullet" id="jah39286-list-0001"><list-item id="jah39286-li-0001"><p>This study shows that age does not modify the impact of aspirin dosing (81&#8201;mg or 325&#8201;mg daily) on cardiovascular outcomes in patients with established cardiovascular disease.</p></list-item><list-item id="jah39286-li-0002"><p>Either dose is associated with a similar risk of death, hospitalization for myocardial infarction, or hospitalization for stroke in this population, irrespective of age.</p></list-item></list>
</p></sec><sec id="jah39286-sec-0007"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah39286-list-0002"><list-item id="jah39286-li-0003"><p>Both the 81&#8201;mg or 325&#8201;mg once daily doses of aspirin can be used in secondary prevention of atherosclerotic cardiovascular disease.</p></list-item></list>
</p></sec></boxed-text>
</p><p>The antiplatelet agent aspirin is recommended in secondary prevention of atherothrombotic events in most patients with established atherosclerotic cardiovascular disease (ASCVD).<xref rid="jah39286-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jah39286-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jah39286-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> It exerts its antithrombotic effect by inhibiting the platelet COX (cyclooxygenase)&#8208;1 enzyme, thereby increasing the risk of bleeding and of gastric mucosal toxicity. In the ADAPTABLE (Aspirin Dosing: A Patient&#8208;Centric Trial Assessing Benefits and Long&#8208;Term Effectiveness) randomized trial, daily aspirin doses of 81&#8201;mg or 325&#8201;mg were associated with similar risks of ischemic events in patients with established ASCVD and with a similar safety profile in terms of bleeding. However, adherence to the 325&#8201;mg dose was lower.<xref rid="jah39286-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>Increasing age is associated with a higher risk of bleeding and gastrointestinal toxicity with antiplatelet therapy<xref rid="jah39286-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jah39286-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah39286-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jah39286-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> and has been identified as a criterion to define high bleeding risk in patients undergoing percutaneous coronary intervention (PCI).<xref rid="jah39286-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jah39286-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> On the other hand, the risk of atherothrombotic cardiovascular events in patients with established ASCVD is proportional to age.<xref rid="jah39286-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jah39286-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jah39286-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Because increasing age is concurrently associated with heightened risks of ischemic and bleeding events,<xref rid="jah39286-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> understanding whether the aspirin dose optimizing net clinical benefits (ischemic and bleeding risks) in secondary prevention is influenced by age would have important clinical implications. Indeed, if the balance between ischemic risk reduction and bleeding risk augmentation with different doses of aspirin varies according to age, tailoring aspirin dose based on age could improve outcomes. Moreover, aspirin bioavailability may vary according to age because age&#8208;related physiological changes can increase (lower hepatic blood flow, delayed gastric emptying) or decrease (increase in gastric pH) drug concentration.<xref rid="jah39286-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jah39286-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jah39286-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jah39286-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>Polypharmacy, a risk factor for nonadherence, is widely prevalent in the aging population, but the effect of age on adherence is inconsistent in the literature.<xref rid="jah39286-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jah39286-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jah39286-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jah39286-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="jah39286-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The importance of appropriate drug adherence on clinical outcomes has been determined in multiple disease states, including in ASCVD.<xref rid="jah39286-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jah39286-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> However, the interplay between age, adherence to different aspirin doses in secondary prevention of ASCVD, and clinical outcomes has not been explored before.</p><p>The objectives of this study are to determine the impact of daily doses of aspirin 81&#8201;mg versus 325&#8201;mg on clinical outcomes according to age and to explore the interplay between age and adherence to aspirin in patients with established ASCVD.</p><sec sec-type="methods" id="jah39286-sec-0008"><title>Methods</title><p>ADAPTABLE was an open&#8208;label, multicenter, patient&#8208;centered, and pragmatic randomized trial comparing daily doses of aspirin of 81 mg versus 325 mg in patients with established ASCVD (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02697916">NCT02697916</ext-link>). The methods and results have been published separately previously.<xref rid="jah39286-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah39286-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> In brief, 15&#8201;076 patients from 40 centers and 1 health plan from the National Patient&#8208;Centered Clinical Research Network were randomized in a 1:1 ratio to either dose of aspirin. Patients were required to have established ASCVD and to have at least 1 enrichment factor (including age &#8805;65&#8201;years) that would further increase their estimated risk of an incident ASCVD event. Baseline demographic characteristics were patient self&#8208;reported, and baseline medical history and comorbidities were ascertained from electronic health records queries. The study end points were captured through a low&#8208;touch, multimodality approach including queries of the electronic health records harmonized into a common data model, linkage with health plan partners, linkage with Centers for Medicare &amp; Medicaid Services claims data, patient&#8208;reported end points from an online patient portal, and remote phone call study visits from the study call center. The primary effectiveness end point was time to death from any cause, hospitalization for myocardial infarction (MI), or hospitalization for stroke. Prespecified secondary effectiveness end points were the individual components of the primary composite end point and coronary revascularization (either PCI or coronary artery bypass graft). The primary safety end point was hospitalizations for bleeding requiring blood product transfusion. Adherence to randomized aspirin dose was evaluated at each participant encounter on the web portal (or via telephone for noninternet participants). For the purpose of this analysis, all patients randomized in ADAPTABLE were included. Age at time of randomization was available for all participants. All participants provided written informed consent. The data that support the findings of this study are available from the corresponding author upon reasonable request. The Duke University institutional review board approved the overall ADAPTABLE program (Pro00068525).</p><sec id="jah39286-sec-0009"><title>Statistical Analysis</title><p>The statistical analysis plan was specified before conducting the analyses but after data collection. Baseline characteristics and parameters of adherence were presented separately for patients &lt;65&#8201;years and &#8805;65&#8201;years. Discrete variables were presented as counts and percentages, and continuous variables as median and interquartile ranges. Chi&#8208;square test was used to compared discrete variables, and the Wilcoxon rank&#8208;sum test was used for continuous variables.</p><p>The association between age and the end points was analyzed using Cox proportional hazard models. The secondary effectiveness end points were compared with the use of the Fine and Gray method to take into account the competing risk of death from any cause. The proportional&#8208;hazards assumption was checked with the use of weighted Schoenfeld residuals. Event counts and cumulative incidence rates estimated at median follow&#8208;up in each treatment group using the Kalbfleisch&#8211;Prentice nonparametric estimator of the cumulative incidence function are presented, as well as unadjusted and adjusted hazard ratios (HRs) and 95% CIs estimated from the models. Because the association between age and risk of end points was not linear, age was parameterized as a linear spline with an inflection point at 65&#8201;years for all end points except for hospitalizations for stroke and coronary revascularization. This parameterization allows for 2 terms for age, to account for the fact that the association between age and end points did not follow the same pattern in these 2 age groups. For the primary and secondary effectiveness end points, adjustment covariates included in the multivariable models were sex, smoking status, internet access at randomization, ethnicity, history of coronary artery disease, MI, coronary artery bypass graft, PCI, cerebrovascular disease, hypertension, hyperlipidemia, atrial fibrillation, congestive heart failure, peripheral artery disease, diabetes, prior aspirin use, race, baseline P2Y12 inhibitor, and body mass index. For the primary safety end point, the number of adjustment covariates included in the model was lower because of the low incidence rate. They were sex, history of coronary artery disease, hypertension, diabetes, medication for stomach upset, history of bleeding, baseline P2Y12 inhibitor, and body mass index. Missing variables were handled using multiple imputation. To assess whether the effect of randomized aspirin dose varies by age, the interaction between age (as a continuous linear variable) and randomized aspirin dose was evaluated in the multivariable models, and <italic toggle="yes">P</italic> values for tests of the interaction are provided. Adjustment covariates included in the multivariable models were sex, smoking status, internet access at randomization, ethnicity, history of coronary artery disease, MI, cerebrovascular disease, hypertension, hyperlipidemia, atrial fibrillation, congestive heart failure, peripheral artery disease, diabetes, prior aspirin use, race, baseline P2Y12 inhibitor, chronic kidney disease, and body mass index.</p><p>To evaluate the interaction between age and randomized dose of aspirin on clinical outcomes accounting for adherence to randomized treatment, 2 sensitivity analyses were performed: a time&#8208;varying analysis where self&#8208;reported aspirin dose was modeled as a time&#8208;dependent exposure, and an <italic toggle="yes">as treated</italic> analysis (based on the time&#8208;varying dose participants were reporting taking, not on the dose they were randomized to).</p><p>All hypothesis tests were 2 sided, and <italic toggle="yes">P</italic> values &lt;0.05 are interpreted as statistically significant without adjustment for multiple comparisons in this exploratory analysis. Analyses were performed using SAS 9.4.</p></sec></sec><sec sec-type="results" id="jah39286-sec-0010"><title>Results</title><p>A total of 15&#8201;076 participants were randomized to aspirin 81&#8201;mg (n=7540) or 325&#8201;mg (n=7536) daily between April 2016 and June 2019. Median follow&#8208;up was 26.2 months (interquartile range: 19.0&#8211;34.9 months) and was similar among participants &lt;65&#8201;years (n=9235 [61.3%]) and &#8805;65&#8201;years (n=9235 [61.3%]; <italic toggle="yes">P</italic>=0.1651). Randomization to both aspirin doses was also similar between patients &lt;65 and &#8805;65&#8201;years (<italic toggle="yes">P</italic>=0.6815). At baseline, patients aged &#8805;65&#8201;years had more peripheral artery disease, atrial fibrillation or flutter, coronary artery disease, hyperlipemia, or chronic kidney disease than patients aged &lt;65&#8201;years, but a lower proportion had diabetes and congestive heart failure (Table&#160;<xref rid="jah39286-tbl-0001" ref-type="table">1</xref>). Patients aged &#8805;65&#8201;years less frequently had a history of bleeding (7.8% versus 9.9%; <italic toggle="yes">P</italic>&lt;0.0001) and significant gastrointestinal bleeding (5.9% versus 7.5%; <italic toggle="yes">P</italic>=0.0001). Concomitant use of a P2Y12 inhibitor was less frequent (19.7% versus 26.1%; <italic toggle="yes">P</italic>&lt;0.0001), but prior aspirin use was more frequent (97.2% versus 94.1%; <italic toggle="yes">P</italic>&lt;0.0001) in patients &#8805;65&#8201;years. Details to adherence according to age and randomized dose are presented in Table&#160;<xref rid="jah39286-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="jah39286-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Baseline Demographic Characteristics, Medical History, and Medications</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Age &lt;65</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Age &#8805;65</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">All patients (N=15&#8201;076)</th><th align="left" rowspan="1" colspan="1">81&#8201;mg (N=2909)</th><th align="left" rowspan="1" colspan="1">325&#8201;mg (N=2932)</th><th align="left" rowspan="1" colspan="1">81&#8201;mg (N=4631)</th><th align="left" rowspan="1" colspan="1">325&#8201;mg (N=4604)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">67.6 (60.7&#8211;73.6)</td><td align="left" rowspan="1" colspan="1">58.6 (53.6&#8211;62.0)</td><td align="left" rowspan="1" colspan="1">58.7 (53.6&#8211;62.0)</td><td align="left" rowspan="1" colspan="1">72.1 (68.7&#8211;76.4)</td><td align="left" rowspan="1" colspan="1">72.0 (68.5&#8211;76.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">4724 (31.3%)</td><td align="left" rowspan="1" colspan="1">1048 (36.0%)</td><td align="left" rowspan="1" colspan="1">1053 (35.9%)</td><td align="left" rowspan="1" colspan="1">1259 (27.2%)</td><td align="left" rowspan="1" colspan="1">1364 (29.6%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Race</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">11&#8201;990 (79.5%)</td><td align="left" rowspan="1" colspan="1">2096 (72.1%)</td><td align="left" rowspan="1" colspan="1">2141 (73.0%)</td><td align="left" rowspan="1" colspan="1">3918 (84.6%)</td><td align="left" rowspan="1" colspan="1">3835 (83.3%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">1311 (8.7%)</td><td align="left" rowspan="1" colspan="1">366 (12.6%)</td><td align="left" rowspan="1" colspan="1">338 (11.5%)</td><td align="left" rowspan="1" colspan="1">298 (6.4%)</td><td align="left" rowspan="1" colspan="1">309 (6.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline P2Y12 inhibitor</td><td align="left" rowspan="1" colspan="1">3051 (22.1%)</td><td align="left" rowspan="1" colspan="1">698 (26.7%)</td><td align="left" rowspan="1" colspan="1">658 (25.5%)</td><td align="left" rowspan="1" colspan="1">858 (19.6%)</td><td align="left" rowspan="1" colspan="1">837 (19.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior aspirin use</td><td align="left" rowspan="1" colspan="1">13&#8201;537 (96.0%)</td><td align="left" rowspan="1" colspan="1">2545 (94.4%)</td><td align="left" rowspan="1" colspan="1">2495 (93.8%)</td><td align="left" rowspan="1" colspan="1">4305 (97.0%)</td><td align="left" rowspan="1" colspan="1">4192 (97.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="left" rowspan="1" colspan="1">90.0 (78.2&#8211;104.1)</td><td align="left" rowspan="1" colspan="1">95.5 (81.8&#8211;110.5)</td><td align="left" rowspan="1" colspan="1">94.5 (81.8&#8211;110.5)</td><td align="left" rowspan="1" colspan="1">87.3 (76.8&#8211;100.0)</td><td align="left" rowspan="1" colspan="1">87.3 (75.9&#8211;100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">30.0 (26.7&#8211;34.4)</td><td align="left" rowspan="1" colspan="1">31.8 (27.8&#8211;36.0)</td><td align="left" rowspan="1" colspan="1">31.5 (27.7&#8211;36.4)</td><td align="left" rowspan="1" colspan="1">29.1 (26.2&#8211;32.9)</td><td align="left" rowspan="1" colspan="1">29.1 (26.1&#8211;33.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">1382 (9.8%)</td><td align="left" rowspan="1" colspan="1">449 (16.6%)</td><td align="left" rowspan="1" colspan="1">436 (16.4%)</td><td align="left" rowspan="1" colspan="1">247 (5.6%)</td><td align="left" rowspan="1" colspan="1">250 (5.8%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Medical history, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Atrial fibrillation/flutter</td><td align="left" rowspan="1" colspan="1">1233 (8.4%)</td><td align="left" rowspan="1" colspan="1">189 (6.6%)</td><td align="left" rowspan="1" colspan="1">190 (6.6%)</td><td align="left" rowspan="1" colspan="1">416 (9.3%)</td><td align="left" rowspan="1" colspan="1">438 (9.8%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coronary artery disease</td><td align="left" rowspan="1" colspan="1">13&#8201;714 (93.5%)</td><td align="left" rowspan="1" colspan="1">2634 (92.4%)</td><td align="left" rowspan="1" colspan="1">2671 (92.9%)</td><td align="left" rowspan="1" colspan="1">4209 (94.0%)</td><td align="left" rowspan="1" colspan="1">4200 (94.2%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior myocardial infarction</td><td align="left" rowspan="1" colspan="1">5305 (36.2%)</td><td align="left" rowspan="1" colspan="1">1226 (43.0%)</td><td align="left" rowspan="1" colspan="1">1252 (43.5%)</td><td align="left" rowspan="1" colspan="1">1448 (32.3%)</td><td align="left" rowspan="1" colspan="1">1379 (30.9%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior percutaneous coronary intervention or coronary artery bypass graft</td><td align="left" rowspan="1" colspan="1">7977 (54.4%)</td><td align="left" rowspan="1" colspan="1">1536 (53.9%)</td><td align="left" rowspan="1" colspan="1">1568 (54.5%)</td><td align="left" rowspan="1" colspan="1">2498 (55.8%)</td><td align="left" rowspan="1" colspan="1">2375 (53.3%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of peripheral artery disease</td><td align="left" rowspan="1" colspan="1">3493 (23.8%)</td><td align="left" rowspan="1" colspan="1">586 (20.5%)</td><td align="left" rowspan="1" colspan="1">631 (21.9%)</td><td align="left" rowspan="1" colspan="1">1120 (25.0%)</td><td align="left" rowspan="1" colspan="1">1156 (25.9%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Congestive heart failure</td><td align="left" rowspan="1" colspan="1">3504 (23.9%)</td><td align="left" rowspan="1" colspan="1">714 (25.0%)</td><td align="left" rowspan="1" colspan="1">783 (27.2%)</td><td align="left" rowspan="1" colspan="1">1004 (22.4%)</td><td align="left" rowspan="1" colspan="1">1003 (22.5%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic kidney disease</td><td align="left" rowspan="1" colspan="1">2648 (18.1%)</td><td align="left" rowspan="1" colspan="1">434 (15.2%)</td><td align="left" rowspan="1" colspan="1">463 (16.1%)</td><td align="left" rowspan="1" colspan="1">881 (19.7%)</td><td align="left" rowspan="1" colspan="1">870 (19.5%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="left" rowspan="1" colspan="1">2778 (18.9%)</td><td align="left" rowspan="1" colspan="1">520 (18.2%)</td><td align="left" rowspan="1" colspan="1">559 (19.4%)</td><td align="left" rowspan="1" colspan="1">819 (18.3%)</td><td align="left" rowspan="1" colspan="1">880 (19.7%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cerebrovascular disease</td><td align="left" rowspan="1" colspan="1">2624 (17.9%)</td><td align="left" rowspan="1" colspan="1">417 (14.6%)</td><td align="left" rowspan="1" colspan="1">421 (14.6%)</td><td align="left" rowspan="1" colspan="1">907 (20.3%)</td><td align="left" rowspan="1" colspan="1">879 (19.7%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">5676 (38.7%)</td><td align="left" rowspan="1" colspan="1">1226 (43.0%)</td><td align="left" rowspan="1" colspan="1">1262 (43.9%)</td><td align="left" rowspan="1" colspan="1">1594 (35.6%)</td><td align="left" rowspan="1" colspan="1">1594 (35.8%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">12&#8201;512 (85.3%)</td><td align="left" rowspan="1" colspan="1">2414 (84.6%)</td><td align="left" rowspan="1" colspan="1">2439 (84.8%)</td><td align="left" rowspan="1" colspan="1">3850 (86.0%)</td><td align="left" rowspan="1" colspan="1">3809 (85.5%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td><td align="left" rowspan="1" colspan="1">12&#8201;946 (88.3%)</td><td align="left" rowspan="1" colspan="1">2459 (86.2%)</td><td align="left" rowspan="1" colspan="1">2497 (86.8%)</td><td align="left" rowspan="1" colspan="1">4013 (89.6%)</td><td align="left" rowspan="1" colspan="1">3977 (89.2%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peptic ulcer disease</td><td align="left" rowspan="1" colspan="1">445 (3.0%)</td><td align="left" rowspan="1" colspan="1">86 (3.0%)</td><td align="left" rowspan="1" colspan="1">93 (3.2%)</td><td align="left" rowspan="1" colspan="1">144 (3.2%)</td><td align="left" rowspan="1" colspan="1">122 (2.7%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of bleeding</td><td align="left" rowspan="1" colspan="1">1267 (8.6%)</td><td align="left" rowspan="1" colspan="1">268 (9.4%)</td><td align="left" rowspan="1" colspan="1">299 (10.4%)</td><td align="left" rowspan="1" colspan="1">334 (7.5%)</td><td align="left" rowspan="1" colspan="1">366 (8.2%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Significant gastrointestinal bleeding</td><td align="left" rowspan="1" colspan="1">950 (6.5%)</td><td align="left" rowspan="1" colspan="1">206 (7.2%)</td><td align="left" rowspan="1" colspan="1">221 (7.7%)</td><td align="left" rowspan="1" colspan="1">249 (5.6%)</td><td align="left" rowspan="1" colspan="1">274 (6.1%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of intracranial hemorrhage</td><td align="left" rowspan="1" colspan="1">208 (1.4%)</td><td align="left" rowspan="1" colspan="1">38 (1.3%)</td><td align="left" rowspan="1" colspan="1">47 (1.6%)</td><td align="left" rowspan="1" colspan="1">60 (1.3%)</td><td align="left" rowspan="1" colspan="1">63 (1.4%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jah39286-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>Adherence to Aspirin by Dose and Age Group</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">Age &lt;65 (N=5841)</th><th align="left" rowspan="1" colspan="1">Age &#8805;65 (N=9235)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Composite adherence outcome<xref rid="jah39286-note-0004" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">Annualized rates and (estimates %)</td><td align="left" rowspan="1" colspan="1">Annualized rates and (estimates %)</td><td align="left" rowspan="1" colspan="1">Gray's test statistic</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">81&#8201;mg</td><td align="left" rowspan="1" colspan="1">531 (12.97)</td><td align="left" rowspan="1" colspan="1">715 (10.20)</td><td align="left" rowspan="1" colspan="1">0.0002<xref rid="jah39286-note-0005" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">325&#8201;mg</td><td align="left" rowspan="1" colspan="1">1389 (43.87)</td><td align="left" rowspan="1" colspan="1">2324 (46.10)</td><td align="left" rowspan="1" colspan="1">0.0618<xref rid="jah39286-note-0005" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Aspirin discontinuation</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">81&#8201;mg</td><td align="left" rowspan="1" colspan="1">324 (7.51)</td><td align="left" rowspan="1" colspan="1">463 (6.35)</td><td align="left" rowspan="1" colspan="1">0.0630<xref rid="jah39286-note-0005" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">325&#8201;mg</td><td align="left" rowspan="1" colspan="1">459 (10.95)</td><td align="left" rowspan="1" colspan="1">731 (10.70)</td><td align="left" rowspan="1" colspan="1">0.9710<xref rid="jah39286-note-0005" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Dose switching</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">81&#8201;mg</td><td align="left" rowspan="1" colspan="1">214 (5.23)</td><td align="left" rowspan="1" colspan="1">264 (3.77)</td><td align="left" rowspan="1" colspan="1">0.0019<xref rid="jah39286-note-0005" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">325&#8201;mg</td><td align="left" rowspan="1" colspan="1">986 (31.14)</td><td align="left" rowspan="1" colspan="1">1722 (34.16)</td><td align="left" rowspan="1" colspan="1">0.0032<xref rid="jah39286-note-0005" ref-type="table-fn">&#8224;</xref>
</td></tr></tbody></table><table-wrap-foot id="jah39286-ntgp-0002"><fn id="jah39286-note-0004"><label>*</label><p>Composite adherence outcome is defined as dose switching or discontinuation occurred when a participant reported a dose different from randomized dose, reported discontinuation of aspirin (permanent or temporary) or never reported aspirin information during follow&#8208;up (missing visits after randomization). Switching dose or discontinuing before withdrawal of consent was counted as a dose switch or discontinuation event. The end of study visit was excluded from defining dose switching and discontinuation because an observed spike in reports of dose switching at the end of study visit seemed to reflect participants' intended dose after trial participation.</p></fn><fn id="jah39286-note-0005"><label>
<sup>&#8224;</sup>
</label><p>Gray's test statistic is reported at 26.2&#8201;months from randomization (the median follow&#8208;up time for all&#8208;cause mortality in ADAPTABLE).</p></fn></table-wrap-foot></table-wrap><p>When analyzing the association between age and clinical outcomes (regardless of aspirin dose), a primary effectiveness end point occurred in 1159 (7.7%) participants (417 in participants aged &lt;65&#8201;years, and 742 in participants aged &#8805;65&#8201;years). Before the age of 65, the risk of a primary effectiveness end point did not significantly increase with age after adjusting for covariates (unadjusted HR for 5&#8208;year age increase, 0.92 [95% CI, 0.87&#8211;0.97]; adjusted HR, 0.94 for 5&#8208;year age increase [95% CI, 0.89&#8211;1.00]). At age 65, the risk of a primary effectiveness end point began to increase significantly with age, with and without covariate adjustment (unadjusted HR, 1.23 [95% CI, 1.16&#8211;1.29]; adjusted HR, 1.21 [95% CI, 1.14&#8211;1.27]). Age was not significantly associated with the risk of the safety end point of hospitalization for bleeding requiring blood product transfusion upon unadjusted and adjusted analyses (<italic toggle="yes">P</italic>&gt;0.05 for age&lt;65 and &#8805;65&#8201;years; Table&#160;<xref rid="jah39286-tbl-0003" ref-type="table">3</xref>). The associations between age and the secondary effectiveness end points are presented in Table&#160;<xref rid="jah39286-tbl-0003" ref-type="table">3</xref>.</p><table-wrap position="float" id="jah39286-tbl-0003" content-type="Table" orientation="portrait"><label>Table 3</label><caption><p>Association Between Age and Ischemic and Bleeding End Points in Patients With Established Atherosclerotic Cardiovascular Disease</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Number of events (%)</th><th align="left" rowspan="1" colspan="1">Unadjusted HR<xref rid="jah39286-note-0007" ref-type="table-fn">*</xref> (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th><th align="left" rowspan="1" colspan="1">Adjusted HR<xref rid="jah39286-note-0007" ref-type="table-fn">*</xref> (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Primary effectiveness end point<xref rid="jah39286-note-0008" ref-type="table-fn">&#8224;</xref> (all&#8208;cause mortality, hospitalization for MI, or hospitalization for stroke)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">417 (7.17%)</td><td align="left" rowspan="1" colspan="1">0.92 (0.87&#8211;0.97)</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">0.94 (0.89&#8211;1.00)</td><td align="left" rowspan="1" colspan="1">0.072</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">742 (7.54%)</td><td align="left" rowspan="1" colspan="1">1.23 (1.16&#8211;1.29)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.21 (1.14&#8211;1.27)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">All&#8208;cause mortality<xref rid="jah39286-note-0008" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">212 (3.56%)</td><td align="left" rowspan="1" colspan="1">0.95 (0.88&#8211;1.03)</td><td align="left" rowspan="1" colspan="1">0.223</td><td align="left" rowspan="1" colspan="1">0.98 (0.90&#8211;1.07)</td><td align="left" rowspan="1" colspan="1">0.681</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">460 (4.46%)</td><td align="left" rowspan="1" colspan="1">1.32 (1.24&#8211;1.41)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.27 (1.18&#8211;1.36)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">Hospitalization for MI<xref rid="jah39286-note-0008" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">176 (3.18%)</td><td align="left" rowspan="1" colspan="1">0.89<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.82&#8211;0.97)</td><td align="left" rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">0.92<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.84&#8211;1.01)</td><td align="left" rowspan="1" colspan="1">0.065</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">265 (2.85%)</td><td align="left" rowspan="1" colspan="1">1.08<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.99&#8211;1.18)</td><td align="left" rowspan="1" colspan="1">0.076</td><td align="left" rowspan="1" colspan="1">1.09<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (1.00&#8211;1.19)</td><td align="left" rowspan="1" colspan="1">0.064</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalization for stroke</td><td align="left" rowspan="1" colspan="1">194 (1.25%)</td><td align="left" rowspan="1" colspan="1">1.06<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.98&#8211;1.15)</td><td align="left" rowspan="1" colspan="1">0.115</td><td align="left" rowspan="1" colspan="1">1.05<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.97&#8211;1.14)</td><td align="left" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary revascularization</td><td align="left" rowspan="1" colspan="1">917 (6.0%)</td><td align="left" rowspan="1" colspan="1">0.96<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.93&#8211;0.99)</td><td align="left" rowspan="1" colspan="1">0.009</td><td align="left" rowspan="1" colspan="1">0.96<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.93&#8211;1.00)</td><td align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" colspan="6" rowspan="1">Primary safety end point<xref rid="jah39286-note-0008" ref-type="table-fn">&#8224;</xref> (hospitalization for bleeding requiring blood product transfusion)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">37 (0.59%)</td><td align="left" rowspan="1" colspan="1">1.25<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.98&#8211;1.58)</td><td align="left" rowspan="1" colspan="1">0.070</td><td align="left" rowspan="1" colspan="1">1.27<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.97&#8211;1.66)</td><td align="left" rowspan="1" colspan="1">0.087</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">60 (0.65%)</td><td align="left" rowspan="1" colspan="1">0.98<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.78&#8211;1.23)</td><td align="left" rowspan="1" colspan="1">0.840</td><td align="left" rowspan="1" colspan="1">0.94<xref rid="jah39286-note-0009" ref-type="table-fn">&#8225;</xref> (0.75&#8211;1.18)</td><td align="left" rowspan="1" colspan="1">0.613</td></tr></tbody></table><table-wrap-foot id="jah39286-ntgp-0003"><fn id="jah39286-note-0006"><p>Cumulative incidence rates were calculated at median follow&#8208;up (26.2 months) using the Kalbfleisch&#8211;Prentice cumulative incidence function estimator. HR&#160;indicates hazard ratio; and MI, myocardial infarction.</p></fn><fn id="jah39286-note-0007"><label>*</label><p>Hazard ratios are reporting the effect of a 5&#8208;year increase in age.</p></fn><fn id="jah39286-note-0008"><label>
<sup>&#8224;</sup>
</label><p>The association between age and risk of these end points was not linear, so age was parameterized as a linear spline with an inflection point at 65&#8201;years. HRs, event counts, and rates are reported separately for age &lt;65 and age &#8805;65. Age is linearly related to stroke and coronary revascularization.</p></fn><fn id="jah39286-note-0009"><label>
<sup>&#8225;</sup>
</label><p>Subdistribution hazard ratio. Number of events are reported at the median time (26.2&#8201;months) for all&#8208;cause mortality.</p></fn></table-wrap-foot></table-wrap><p>Among participants aged &lt;65&#8201;years, a primary end point event occurred in 226 (7.5%) participants in the 81 mg group and in 191 (6.8%) participants in the 325 mg group. Among participants aged &#8805;65&#8201;years, a primary end point event occurred in 364 (7.1%) participants in the 81 mg group and in 378 (8.0%) participants in the 325&#8201;mg group. The effect of randomized aspirin dose did not vary significantly by age (adjusted <italic toggle="yes">P</italic> value for interaction=0.559). Among participants aged &lt;65&#8201;years, a primary safety bleeding event occurred in 19 (0.5%) in the 81 mg group, and 18 (0.7%) in the 325 mg group; and for participants aged &#8805;65&#8201;years, the primary safety bleeding event occurred in 34 (0.7%) in the 81&#8201;mg group and 26 (0.6%) in the 325&#8201;mg group. The effect of randomized aspirin dose on the primary safety bleeding event did not vary by age (adjusted <italic toggle="yes">P</italic> value for interaction=0.486). There was no significant interaction between age and the randomized aspirin dose for any of the secondary end points (<italic toggle="yes">P</italic>&gt;0.05 for all) (Table&#160;<xref rid="jah39286-tbl-0004" ref-type="table">4</xref>). Cumulative incidence curves by randomized aspirin dose group and age group are presented in Figure&#160;<xref rid="jah39286-supitem-0001" ref-type="supplementary-material">S1</xref> through <xref rid="jah39286-supitem-0001" ref-type="supplementary-material">S3</xref> for the primary efficacy end point, all&#8208;cause death, and the primary safety end point. Event rates according to aspirin dose in patients &lt;75&#8201;years or &#8805;75&#8201;years are presented in Table&#160;<xref rid="jah39286-supitem-0001" ref-type="supplementary-material">S1&#8211;S3</xref>.</p><table-wrap position="float" id="jah39286-tbl-0004" content-type="Table" orientation="portrait"><label>Table 4</label><caption><p>Interaction Between Age and Randomized Aspirin Dose (81&#8201;mg vs 325&#8201;mg Daily) in Patients With Established Atherosclerotic Cardiovascular Disease</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Number of events (%)</th><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">81&#8201;mg vs 325&#8201;mg Hazard ratio [95% CI] (adjusted analysis)</th><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">Overall <italic toggle="yes">P</italic> value for age&#8211;dose interaction</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">81&#8201;mg</th><th align="left" rowspan="1" colspan="1">325&#8201;mg</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Primary effectiveness end point<xref rid="jah39286-note-0012" ref-type="table-fn">&#8224;</xref> (all&#8208;cause mortality, hospitalization for MI, or hospitalization for stroke)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">226 (7.54%)</td><td align="left" rowspan="1" colspan="1">191 (6.80%)</td><td align="left" rowspan="1" colspan="1">1.23 (1.01&#8211;1.49)</td><td align="left" rowspan="2" colspan="1">0.559</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">364 (7.12%)</td><td align="left" rowspan="1" colspan="1">378 (7.96%)</td><td align="left" rowspan="1" colspan="1">0.95 (0.82&#8211;1.10)</td></tr><tr><td align="left" colspan="5" rowspan="1">All&#8208;cause death<xref rid="jah39286-note-0012" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">107 (3.52%)</td><td align="left" rowspan="1" colspan="1">105 (3.59%)</td><td align="left" rowspan="1" colspan="1">1.06 (0.81&#8211;1.39)</td><td align="left" rowspan="2" colspan="1">0.893</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">208 (3.97%)</td><td align="left" rowspan="1" colspan="1">252 (4.96%)</td><td align="left" rowspan="1" colspan="1">0.82 (0.68&#8211;0.98)</td></tr><tr><td align="left" colspan="5" rowspan="1">Hospitalization for MI<xref rid="jah39286-note-0012" ref-type="table-fn">&#8224;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">91 (3.32%)</td><td align="left" rowspan="1" colspan="1">85 (3.03%</td><td align="left" rowspan="1" colspan="1">1.09<xref rid="jah39286-note-0013" ref-type="table-fn">&#8225;</xref> (0.81&#8211;1.47)</td><td align="left" rowspan="2" colspan="1">0.702</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">137 (2.85%)</td><td align="left" rowspan="1" colspan="1">128 (2.86%)</td><td align="left" rowspan="1" colspan="1">1.06<xref rid="jah39286-note-0013" ref-type="table-fn">&#8225;</xref> (0.83&#8211;1.35)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalization for stroke<xref rid="jah39286-note-0011" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">102 (1.23%)</td><td align="left" rowspan="1" colspan="1">92 (1.27%)</td><td align="left" rowspan="1" colspan="1">1.09<xref rid="jah39286-note-0013" ref-type="table-fn">&#8225;</xref> (0.82&#8211;1.45)</td><td align="left" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary revascularization<xref rid="jah39286-note-0011" ref-type="table-fn">*</xref>
</td><td align="left" rowspan="1" colspan="1">471 (6.05%)</td><td align="left" rowspan="1" colspan="1">446 (5.96%)</td><td align="left" rowspan="1" colspan="1">1.04<xref rid="jah39286-note-0013" ref-type="table-fn">&#8225;</xref> (0.92&#8211;1.19)</td><td align="left" rowspan="1" colspan="1">0.574</td></tr><tr><td align="left" colspan="5" rowspan="1">Primary safety end point<xref rid="jah39286-note-0012" ref-type="table-fn">&#8224;</xref> (hospitalization for bleeding requiring blood product transfusion)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &lt;65</td><td align="left" rowspan="1" colspan="1">19 (0.53%)</td><td align="left" rowspan="1" colspan="1">18 (0.65%)</td><td align="left" rowspan="1" colspan="1">1.08<xref rid="jah39286-note-0013" ref-type="table-fn">&#8225;</xref> (0.56&#8211;2.07)</td><td align="left" rowspan="2" colspan="1">0.486</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age &#8805;65</td><td align="left" rowspan="1" colspan="1">34 (0.71%)</td><td align="left" rowspan="1" colspan="1">26 (0.59%)</td><td align="left" rowspan="1" colspan="1">1.32<xref rid="jah39286-note-0013" ref-type="table-fn">&#8225;</xref> (0.80&#8211;2.20)</td></tr></tbody></table><table-wrap-foot id="jah39286-ntgp-0004"><fn id="jah39286-note-0010"><p>MI indicates myocardial infarction. Cumulative incidence rates were calculated at median follow&#8208;up (26.2&#8201;months) using the Kalbfleisch&#8211;Prentice cumulative incidence function estimator.</p></fn><fn id="jah39286-note-0011"><label>*</label><p>From the primary analysis of the ADAPTABLE (Aspirin Dosing: A Patient&#8208;Centric Trial Assessing Benefits and Long&#8208;Term Effectiveness) trial.<xref rid="jah39286-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p></fn><fn id="jah39286-note-0012"><label>
<sup>&#8224;</sup>
</label><p>The association between age and risk of these end points was not linear, so age was parameterized as a linear spline with an inflection point at 65&#8201;years. Hazard ratios, event counts, and rates are reported separately for age &lt;65 and age &#8805;65. However, the age&#8208;dose interaction was assessed across age groups using a single linear term for age.</p></fn><fn id="jah39286-note-0013"><label>
<sup>&#8225;</sup>
</label><p>Subdistribution hazard ratio.</p></fn></table-wrap-foot></table-wrap><p>In both age groups, 67.1% of participants remained on the assigned study drug without switching dose or discontinuing aspirin throughout the trial (<italic toggle="yes">P</italic>=0.963). Among participants &lt;65&#8201;years, 720 (12.3%) discontinued aspirin, and 1200 switched dose (20.5%); among participants &#8805;65&#8201;years, 1053 (11.4%) discontinued aspirin, and 1986 (21.5%) switched dose (<italic toggle="yes">P</italic>=0.125). However, median time to discontinuation or dose switch was lower in patients &lt;65&#8201;years (12.8 months; interquartile range: 6.1&#8211;24.0 months) compared with those &#8805;65&#8201;years (15.0 months; interquartile range: 6.3&#8211;24.0 months; <italic toggle="yes">P</italic>&lt;0.001). In sensitivity analyses modeling self&#8208;reported aspirin dose as a time&#8208;varying exposure, there was no significant interaction between age and self&#8208;reported aspirin dose for the primary effectiveness and safety end points (Table&#160;<xref rid="jah39286-supitem-0001" ref-type="supplementary-material">S2</xref>). There was no significant interaction between age and randomized aspirin dose for the primary effectiveness end point in the <italic toggle="yes">as treated</italic> analysis (Table&#160;<xref rid="jah39286-supitem-0001" ref-type="supplementary-material">S3</xref>).</p></sec><sec sec-type="discussion" id="jah39286-sec-0011"><title>Discussion</title><p>In this secondary analysis of the pragmatic, multicenter ADAPTABLE randomized trial, the main findings are that, in patients with established ASCVD: (1) there is no interaction between age and daily aspirin doses of 81&#8201;mg or 325 mg in terms of effectiveness and safety; and (2) adherence to the randomized dose of aspirin was similar in both age groups. As a secondary analysis of a trial that did not show a difference in safety and efficacy outcomes between both doses of aspirin, these findings need to be interpreted as hypothesis generating and exploratory.</p><p>Strategies to minimize bleeding risk while maintaining appropriate antithrombotic protection is critical, particularly in elderly individuals, a population at higher risk of bleeding and ischemic events.<xref rid="jah39286-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Until recently, there remained a clinical equipoise in the United States regarding the favored aspirin dose at discharge after an MI, with doses of 81 mg and 325&#8201;mg used in 35.6% and 60.9% of patients, respectively.<xref rid="jah39286-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The main analysis of the ADAPTABLE trial demonstrated that there were no significant differences in the risk of cardiovascular events or of hospitalizations for bleeding requiring transfusions between patients randomized to 81&#8201;mg and those randomized to 325&#8201;mg of aspirin daily, and our secondary analysis confirms that these results are consistent regardless of the age of the patient.<xref rid="jah39286-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> These findings have important implications given that older patients generally tend to have higher risks of both bleeding and ischemic events compared with younger patients while on antiplatelet therapy,<xref rid="jah39286-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jah39286-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jah39286-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jah39286-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> making antithrombotic decisions more challenging in this vulnerable subset. More specifically, gastrointestinal toxicity of aspirin increases with age,<xref rid="jah39286-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jah39286-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="jah39286-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> which translates into more bleeding, as suggested by subgroup analysis of a large&#8208;scale primary prevention trial in which the risk of major bleeding with aspirin increased with age.<xref rid="jah39286-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> We thus confirmed that aspirin doses of 81&#8201;mg or 325&#8201;mg both represent an appropriate choice in secondary prevention of ASCVD across the age spectrum.</p><p>In this analysis, the association between age and the primary effectiveness end point was nonlinear, with age being a risk factor only among those &#8805;65&#8201;years (regardless of aspirin dose). In the latter subgroup, all&#8208;cause mortality was significantly and independently associated with increasing age but not the other components of the primary effectiveness end point. Although we previously demonstrated that the positive predictive value of the method for end point ascertainment used in ADAPTABLE (queries National Patient&#8208;Centered Clinical Research Network's common data model) was accurate to identify MI hospitalizations, capture of stroke events was suboptimal when nonprimary diagnoses were included in the definition.<xref rid="jah39286-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Whether increasing age would have been associated with a significant increase in the risk of the latter if end points have been adjudicated remains speculative.</p><p>In the ADAPTABLE trial, the incidence of the primary bleeding end point was low (&lt;1% incidence) and similar between study arms (<italic toggle="yes">P</italic>=0.41).<xref rid="jah39286-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> This association was not modified by age in this secondary analysis (<italic toggle="yes">P</italic> value for interaction=0.413 in patients &lt;65&#8201;years, and 0.942 in patients &#8805;65&#8201;years). Only hospitalizations for bleeding requiring blood product transfusions were included in the definition of bleeding in ADAPTABLE, because clinical end points were ascertained through queries of National Patient&#8208;Centered Clinical Research Network's harmonized electronic health records database. Other types of clinically relevant bleeding events that were not associated with blood product transfusions might have occurred in an imbalanced fashion across aspirin assignment groups (81&#8201;mg versus 325&#8201;mg daily), but, by design, these data were not available in this study. The bleeding definition used in ADAPTABLE may have been insensitive, and a more liberal capture of moderate bleeds could have theoretically yielded larger differences in HRs. The 325&#8201;mg dose of aspirin does not induce additional COX&#8208;1 inhibition compared with the 81&#8201;mg dose, yet its selectivity shifts to COX&#8208;2 inhibition.<xref rid="jah39286-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> How this shift in COX selectivity with different aspirin doses translates into differences into clinically relevant bleeding events that do not necessarily require blood product transfusions in older patients remains to be studied. Because of this limitation, no definitive conclusion can be drawn from our data regarding safety of the 2 aspirin doses according to age.</p><p>Emerging antithrombotic strategies in patients with established ASCVD have recently been investigated and incorporated into clinical practice guidelines.<xref rid="jah39286-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="jah39286-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> In the COMPASS (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease) trial, the combination of rivaroxaban 2.5&#8201;mg twice daily and aspirin 100&#8201;mg once daily was associated with a lower rate of the composite of cardiovascular death, stroke, or MI compared with aspirin alone in patients with stable ASCVD, at the expense of a higher risk of bleeding.<xref rid="jah39286-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Although the nominal <italic toggle="yes">P</italic> value for interaction between age and the treatment assignment was not significant (<italic toggle="yes">P</italic>=0.20), there was a gradient of the magnitude of the treatment effect, with a significant reduction in clinical events with the rivaroxaban+aspirin strategy over aspirin alone in patients &lt;65&#8201;years (HR, 0.63 [95% CI, 0.48&#8211;0.84]) and 65 to 74&#8201;years (HR, 0.74 [95% CI, 0.61&#8211;0.90]) but not in those &#8805;75&#8201;years (HR, 0.89 [95% CI, 0.69&#8211;1.14]). Novel aspirin&#8208;free antithrombotic strategies have also been studied in patients using a P2Y12 inhibitor after PCI.<xref rid="jah39286-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="jah39286-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="jah39286-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> In the TWILIGHT (Ticagrelor With Aspirin or Alone in High&#8208;Risk Patients After Coronary Intervention) trial, age was not an effect modifier on bleeding and ischemic events in the comparison between ticagrelor+aspirin versus ticagrelor+placebo after 3&#8201;months of dual antiplatelet therapy following PCI.<xref rid="jah39286-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Recently, a new pharmaceutical lipid&#8208;aspirin complex liquid formulation with the potential to reduce gastric toxicity has been developed that has been shown to significantly reduce the risk of upper gastrointestinal erosions or ulcers compared with standard, immediate&#8208;release aspirin.<xref rid="jah39286-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="jah39286-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> This formulation might be of particular interest for the elderly population at increased bleeding risk, but no specific data on the interaction between age and pharmaceutical lipid&#8208;aspirin formulation are available, to our knowledge.</p><sec id="jah39286-sec-0012"><title>Limitations</title><p>The following limitations to this analysis should be noted. First, randomization was not stratified based on age subgroups, thus the comparison between aspirin dose assignment and outcomes within age groups should be viewed as observational only. To attenuate this limitation, a multivariable analysis was performed to adjust for potential confounding factors that were available within the data set. Second, as previously mentioned, clinically relevant bleeding events that did not require a hospitalization and blood product transfusions were not captured as part of the safety end point; therefore, the potential modifying effect of age on aspirin dose in terms of other types of bleeding could not be assessed. Because of this limitation, and of the nonadherence rates between randomized groups, it cannot be ruled out that the 325&#8201;mg dose increases bleeding in general and in particular in the elderly. Third, adherence to the randomized aspirin dose was not similar across age groups. This may have occurred because of differential incident indication for oral anticoagulation across age groups during the course of the trial, but prescription data are not available. However, there remained no significant interaction between age and aspirin dose in 2 different sensitivity analyses accounting for adherence. Fourth, at last study visit, 22.3% of participants &lt;65&#8201;years were not using the online patient portal to capture patient&#8208;reported end points, versus 24.8% of participants &#8805;65&#8201;years (<italic toggle="yes">P</italic>=0.0006). How this small magnitude difference in the end point capture methods between age groups affected the results remains uncertain, but its impact is expected to be minor because the patient portal was not the primary method for end point capture in ADAPTABLE. Finally, age &#8805;65&#8201;years was an enrichment criteria for inclusion in the study. Therefore, by design, participants &lt;65&#8201;years are more likely to bear additional enrichment criteria and to present more comorbidities. Therefore, the analysis by age might not truly reflect what would be observed in the general public.</p></sec></sec><sec sec-type="conclusions" id="jah39286-sec-0013"><title>Conclusions</title><p>In conclusion, in patients with established ASCVD, there are no age&#8208;related significant differences in cardiovascular events or in hospitalizations for bleeding requiring blood product transfusions between daily doses of aspirin of 81&#8201;mg or 325&#8201;mg. The optimal antithrombotic regimen in older patients with stable ASCVD according to age remains to be studied in properly powered randomized trials.</p></sec><sec id="jah39286-sec-0014"><title>Sources of Funding</title><p>This work was supported by the Patient&#8208;Centered Outcomes Research Institute.</p></sec><sec id="jah39286-sec-0015"><title>Disclosures</title><p>Dr Marquis&#8208;Gravel reports honoraria from Pharmascience, JAMP Pharma, Bayer, KYE, Novartis, Population Health Research Institute, and Canadian Heart Research Center; research funding from Canadian Institutes of Health Research, Fonds de Recherche du Qu&#233;bec&#8211;Sant&#233;, Duke Clinical Research Institute, Bayer, Universit&#233; de Montr&#233;al, and Montreal Heart Institute. Dr Roe reports Verana Health (employee and stock options), Novo Nordisk (honoraria for clinical end point adjudication activities), and Regeneron (honoraria for serving on a data safety and monitoring committee). Dr Effron reports equity in and receives a pension from Eli Lilly and Company. Dr Girotra is funded by the National Heart, Lung, and Blood Institute (R56HL158803) and receives funding from the American Heart Association for editorial work. Dr Jain reports being research principal investigator for Medtronic, Boston Scientific, and Abbott. Dr Rothman declares family&#8208;owned stocks from Moderna (not related to this study). Dr Jones reports grants from Patient&#8208;Centered Outcomes Research Institute during the conduct of the study; grants from Boehringer Ingelheim, grants and personal fees from Bayer, grants and personal fees from Janssen Pharmaceuticals, personal fees from Bristol&#8208;Myers Squibb, grants from Merck, and personal fees from Medscape, outside the submitted work. The remaining authors have no disclosures to report.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jah39286-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Tables S1&#8211;S3.</p><p>Figures&#160;S1&#8211;S3.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JAH3-13-e026921-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah39286-bibl-0001"><title>References</title><ref id="jah39286-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah39286-cit-0001"><string-name name-style="western"><surname>Levine</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Bates</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Bittl</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Brindis</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Fihn</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Fleisher</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Lange</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Mauri</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>134</volume>:<fpage>e123</fpage>&#8211;<lpage>e155</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000404</pub-id><pub-id pub-id-type="pmid">27026020</pub-id></mixed-citation></ref><ref id="jah39286-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah39286-cit-0002"><string-name name-style="western"><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bueno</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Collet</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Costa</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jeppsson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Juni</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kastrati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kolh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mauri</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease</article-title>. <source>Eur Heart J</source>. <year>2018</year>;<volume>39</volume>:<fpage>213</fpage>&#8211;<lpage>260</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehx419</pub-id><pub-id pub-id-type="pmid">29088328</pub-id></mixed-citation></ref><ref id="jah39286-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah39286-cit-0003"><string-name name-style="western"><surname>Marquis&#8208;Gravel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Levine</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Neumann</surname><given-names>F&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Costa</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lordkipanidz&#233;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Roffi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>SD</given-names></string-name>, et&#160;al. <article-title>A critical comparison of Canadian and international guidelines recommendations for antiplatelet therapy in coronary artery disease</article-title>. <source>Can J Cardiol</source>. <year>2020</year>;<volume>36</volume>:<fpage>1298</fpage>&#8211;<lpage>1307</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cjca.2019.12.013</pub-id><pub-id pub-id-type="pmid">32553812</pub-id></mixed-citation></ref><ref id="jah39286-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah39286-cit-0004"><string-name name-style="western"><surname>Jones</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Mulder</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wruck</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Kripalani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Crenshaw</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Effron</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Re</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Comparative effectiveness of aspirin dosing in cardiovascular disease</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>:<fpage>1981</fpage>&#8211;<lpage>1990</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2102137</pub-id><pub-id pub-id-type="pmid">33999548</pub-id><pub-id pub-id-type="pmcid">PMC9908069</pub-id></mixed-citation></ref><ref id="jah39286-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah39286-cit-0005"><string-name name-style="western"><surname>Costa</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>van Klaveren</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Heg</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Raber</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Feres</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pilgrim</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Colombo</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE&#8208;DAPT) score: a pooled analysis of individual&#8208;patient datasets from clinical trials</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>389</volume>:<fpage>1025</fpage>&#8211;<lpage>1034</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(17)30397-5</pub-id><pub-id pub-id-type="pmid">28290994</pub-id></mixed-citation></ref><ref id="jah39286-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah39286-cit-0006"><string-name name-style="western"><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Normand</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Gershlick</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Spertus</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Rinaldi</surname><given-names>MJ</given-names></string-name>, et&#160;al. <article-title>Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention</article-title>. <source>J Am Med Assoc</source>. <year>2016</year>;<volume>315</volume>:<fpage>1735</fpage>&#8211;<lpage>1749</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2016.3775</pub-id><pub-id pub-id-type="pmcid">PMC5408574</pub-id><pub-id pub-id-type="pmid">27022822</pub-id></mixed-citation></ref><ref id="jah39286-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah39286-cit-0007"><string-name name-style="western"><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Ohman</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Hochman</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Gottlieb</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Dalby</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Boden</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>HD</given-names></string-name>, et&#160;al. <article-title>Elderly patients with acute coronary syndromes managed without revascularization</article-title>. <source>Circulation</source>. <year>2013</year>;<volume>128</volume>:<fpage>823</fpage>&#8211;<lpage>833</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.002303</pub-id><pub-id pub-id-type="pmid">23852610</pub-id></mixed-citation></ref><ref id="jah39286-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah39286-cit-0008"><string-name name-style="western"><surname>Ibanez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vidal</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Vendrell</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Moretti</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Laporte</surname><given-names>JR</given-names></string-name>. <article-title>Upper gastrointestinal bleeding associated with antiplatelet drugs</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2006</year>;<volume>23</volume>:<fpage>235</fpage>&#8211;<lpage>242</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02759.x</pub-id><pub-id pub-id-type="pmid">16393302</pub-id></mixed-citation></ref><ref id="jah39286-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah39286-cit-0009"><string-name name-style="western"><surname>Urban</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Colleran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Capodanno</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cuisset</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cutlip</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Eerdmans</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Eikelboom</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Defining high bleeding risk in patients undergoing percutaneous coronary intervention. A consensus document from the Academic Research Consortium for high bleeding risk</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>140</volume>:<fpage>240</fpage>&#8211;<lpage>261</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.040167</pub-id><pub-id pub-id-type="pmid">31116032</pub-id><pub-id pub-id-type="pmcid">PMC6636810</pub-id></mixed-citation></ref><ref id="jah39286-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah39286-cit-0010"><string-name name-style="western"><surname>Varenne</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sideris</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kedev</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cuisset</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Carrie</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hovasse</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Garot</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>El Mahmoud</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Spaulding</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Drug&#8208;eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single&#8208;blind trial</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>41</fpage>&#8211;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32713-7</pub-id><pub-id pub-id-type="pmid">29102362</pub-id></mixed-citation></ref><ref id="jah39286-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah39286-cit-0011"><string-name name-style="western"><surname>Minges</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Herrin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fiorilli</surname><given-names>PN</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname><given-names>JP</given-names></string-name>. <article-title>Development and validation of a simple risk score to predict 30&#8208;day readmission after percutaneous coronary intervention in a cohort of medicare patients</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2017</year>;<volume>89</volume>:<fpage>955</fpage>&#8211;<lpage>963</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ccd.26701</pub-id><pub-id pub-id-type="pmid">27515069</pub-id><pub-id pub-id-type="pmcid">PMC5397364</pub-id></mixed-citation></ref><ref id="jah39286-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah39286-cit-0012"><string-name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Alonso</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bittencourt</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Callaway</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Carson</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Chamberlain</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>SR</given-names></string-name>, et&#160;al. <article-title>Heart disease and stroke statistics&#8212;2019 update: a report from the American Heart Association</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>139</volume>:<fpage>e56</fpage>&#8211;<lpage>e528</lpage>.<pub-id pub-id-type="pmid">30700139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000659</pub-id></mixed-citation></ref><ref id="jah39286-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="jah39286-cit-0013"><collab collab-type="authors">Health Resources &amp; Services Administration</collab>
. <article-title>Federal office of rural health policy (FORHP) data files</article-title>. <year>2018</year>&#8208;2019 Accessed January 9, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hrsa.gov/rural-health/about-us/what-is-rural/data-files" ext-link-type="uri">https://www.hrsa.gov/rural&#8208;health/about&#8208;us/what&#8208;is&#8208;rural/data&#8208;files</ext-link>.</mixed-citation></ref><ref id="jah39286-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah39286-cit-0014"><string-name name-style="western"><surname>Capranzano</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>. <article-title>Antithrombotic management of elderly patients with coronary artery disease</article-title>. <source>J Am Coll Cardiol Interv</source>. <year>2021</year>;<volume>14</volume>:<fpage>723</fpage>&#8211;<lpage>738</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2021.01.040</pub-id><pub-id pub-id-type="pmid">33826494</pub-id></mixed-citation></ref><ref id="jah39286-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah39286-cit-0015"><string-name name-style="western"><surname>Schmucker</surname><given-names>DL</given-names></string-name>. <article-title>Age&#8208;related changes in liver structure and function: implications for disease ?</article-title><source>Exp Gerontol</source>. <year>2005</year>;<volume>40</volume>:<fpage>650</fpage>&#8211;<lpage>659</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exger.2005.06.009</pub-id><pub-id pub-id-type="pmid">16102930</pub-id></mixed-citation></ref><ref id="jah39286-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah39286-cit-0016"><string-name name-style="western"><surname>Capodanno</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>. <article-title>Antithrombotic therapy in the elderly</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>:<fpage>1683</fpage>&#8211;<lpage>1692</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2010.04.063</pub-id><pub-id pub-id-type="pmid">21070918</pub-id></mixed-citation></ref><ref id="jah39286-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah39286-cit-0017"><string-name name-style="western"><surname>McLean</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Le Couteur</surname><given-names>DG</given-names></string-name>. <article-title>Aging biology and geriatric clinical pharmacology</article-title>. <source>Pharmacol Rev</source>. <year>2004</year>;<volume>56</volume>:<fpage>163</fpage>&#8211;<lpage>184</lpage>. doi: <pub-id pub-id-type="doi">10.1124/pr.56.2.4</pub-id><pub-id pub-id-type="pmid">15169926</pub-id></mixed-citation></ref><ref id="jah39286-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah39286-cit-0018"><string-name name-style="western"><surname>Karakaya</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Van Tielen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Umbach</surname><given-names>I</given-names></string-name>. <article-title>Risk factors associated with medication non&#8208;compliance in arterial hypertension</article-title>. <source>J Hypertens</source>. <year>2016</year>;<volume>34</volume>:<fpage>e72</fpage>. doi: <pub-id pub-id-type="doi">10.1097/01.hjh.0000491524.57465.cc</pub-id></mixed-citation></ref><ref id="jah39286-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah39286-cit-0019"><string-name name-style="western"><surname>Lau</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Beuning</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Postma&#8208;Lim</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Klein&#8208;Beernink</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>de Boer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Porsius</surname><given-names>A</given-names></string-name>. <article-title>Non&#8208;compliance in elderly people: evaluation of risk factors by longitudinal data analysis</article-title>. <source>Pharm World Sci</source>. <year>1996</year>;<volume>18</volume>:<fpage>63</fpage>&#8211;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF00579707</pub-id><pub-id pub-id-type="pmid">8739259</pub-id></mixed-citation></ref><ref id="jah39286-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah39286-cit-0020"><string-name name-style="western"><surname>Krueger</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Botermann</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schorr</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Griese&#8208;Mammen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Laufs</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>M</given-names></string-name>. <article-title>Age&#8208;related medication adherence in patients with chronic heart failure: a systematic literature review</article-title>. <source>Int J Cardiol</source>. <year>2015</year>;<volume>184</volume>:<fpage>728</fpage>&#8211;<lpage>735</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijcard.2015.03.042</pub-id><pub-id pub-id-type="pmid">25795085</pub-id></mixed-citation></ref><ref id="jah39286-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah39286-cit-0021"><string-name name-style="western"><surname>Al AlShaikh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Walters</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>J</given-names></string-name>. <article-title>Predictive factors of non&#8208;adherence to secondary preventative medication after stroke or transient ischaemic attack: a systematic review and meta&#8208;analyses</article-title>. <source>Eur Stroke J</source>. <year>2016</year>;<volume>1</volume>:<fpage>65</fpage>&#8211;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1177/2396987316647187</pub-id><pub-id pub-id-type="pmid">29900404</pub-id><pub-id pub-id-type="pmcid">PMC5992740</pub-id></mixed-citation></ref><ref id="jah39286-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah39286-cit-0022"><string-name name-style="western"><surname>Lopes</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>P</given-names></string-name>. <article-title>Determinants of non&#8208;adherence to the medications for dyslipidemia: a systematic review</article-title>. <source>Patient Prefer Adherence</source>. <year>2021</year>;<volume>15</volume>:<fpage>1853</fpage>&#8211;<lpage>1871</lpage>. doi: <pub-id pub-id-type="doi">10.2147/PPA.S319604</pub-id><pub-id pub-id-type="pmid">34465984</pub-id><pub-id pub-id-type="pmcid">PMC8403077</pub-id></mixed-citation></ref><ref id="jah39286-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah39286-cit-0023"><string-name name-style="western"><surname>Ruppar</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Cooper</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Mehr</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Delgado</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Dunbar&#8208;Jacob</surname><given-names>JM</given-names></string-name>. <article-title>Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta&#8208;analysis of controlled trials</article-title>. <source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>:<elocation-id>e002606</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.115.002606</pub-id><pub-id pub-id-type="pmid">27317347</pub-id><pub-id pub-id-type="pmcid">PMC4937243</pub-id></mixed-citation></ref><ref id="jah39286-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah39286-cit-0024"><string-name name-style="western"><surname>Rodriguez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Maron</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Knowles</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Virani</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Heidenreich</surname><given-names>PA</given-names></string-name>. <article-title>Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease</article-title>. <source>JAMA Cardiol</source>. <year>2019</year>;<volume>4</volume>:<fpage>206</fpage>&#8211;<lpage>213</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamacardio.2018.4936</pub-id><pub-id pub-id-type="pmid">30758506</pub-id><pub-id pub-id-type="pmcid">PMC6439552</pub-id></mixed-citation></ref><ref id="jah39286-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah39286-cit-0025"><string-name name-style="western"><surname>Marquis&#8208;Gravel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Harrington</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Berdan</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Hammill</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Faulkner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fonarow</surname><given-names>GC</given-names></string-name>, et&#160;al. <article-title>Rationale and design of the aspirin dosing&#8212;a patient&#8208;centric trial assessing benefits and long&#8208;term effectiveness (ADAPTABLE) trial</article-title>. <source>JAMA Cardiol</source>. <year>2020</year>;<volume>5</volume>:<fpage>598</fpage>&#8211;<lpage>607</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamacardio.2020.0116</pub-id><pub-id pub-id-type="pmid">32186653</pub-id></mixed-citation></ref><ref id="jah39286-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah39286-cit-0026"><string-name name-style="western"><surname>Marquis&#8208;Gravel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dalgaard</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Lokhnygina</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Harrington</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Wallentin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Storey</surname><given-names>RF</given-names></string-name>, et&#160;al. <article-title>Post&#8208;discharge bleeding and subsequent mortality after acute coronary syndrome treated with or without PCI</article-title>. <source>J Am Coll Cardiol</source>. <year>2020</year>;<volume>76</volume>:<fpage>162</fpage>&#8211;<lpage>171</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2020.05.031</pub-id><pub-id pub-id-type="pmid">32646565</pub-id></mixed-citation></ref><ref id="jah39286-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah39286-cit-0027"><string-name name-style="western"><surname>Hall</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>de Lemos</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Enriquez</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>McGuire</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Desai</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>SR</given-names></string-name>. <article-title>Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the national cardiovascular data registry (NCDR)</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2014</year>;<volume>7</volume>:<fpage>701</fpage>&#8211;<lpage>707</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.113.000822</pub-id><pub-id pub-id-type="pmid">25116897</pub-id></mixed-citation></ref><ref id="jah39286-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah39286-cit-0028"><string-name name-style="western"><surname>Baber</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Giustino</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Henry</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Sartori</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ariti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Litherland</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dangas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gibson</surname><given-names>CM</given-names></string-name>, et&#160;al. <article-title>Coronary thrombosis and major bleeding after PCI with drug&#8208;eluting stents: risk scores from PARIS</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>:<fpage>2224</fpage>&#8211;<lpage>2234</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2016.02.064</pub-id><pub-id pub-id-type="pmid">27079334</pub-id></mixed-citation></ref><ref id="jah39286-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah39286-cit-0029"><string-name name-style="western"><surname>Hern&#225;ndez&#8208;D&#237;az</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a Rodr&#237;guez</surname><given-names>LA</given-names></string-name>. <article-title>Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications</article-title>. <source>BMC Med</source>. <year>2006</year>;<volume>4</volume>:<fpage>22</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1741-7015-4-22</pub-id><pub-id pub-id-type="pmid">16987411</pub-id><pub-id pub-id-type="pmcid">PMC1590044</pub-id></mixed-citation></ref><ref id="jah39286-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah39286-cit-0030"><string-name name-style="western"><surname>Lavie</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Howden</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Scheiman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tursi</surname><given-names>J</given-names></string-name>. <article-title>Upper gastrointestinal toxicity associated with long&#8208;term aspirin therapy: consequences and prevention</article-title>. <source>Curr Probl Cardiol</source>. <year>2017</year>;<volume>42</volume>:<fpage>146</fpage>&#8211;<lpage>164</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cpcardiol.2017.01.006</pub-id><pub-id pub-id-type="pmid">28363584</pub-id></mixed-citation></ref><ref id="jah39286-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah39286-cit-0031"><article-title>Effects of aspirin for primary prevention in persons with diabetes mellitus</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>1529</fpage>&#8211;<lpage>1539</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1804988</pub-id><pub-id pub-id-type="pmid">30146931</pub-id></mixed-citation></ref><ref id="jah39286-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah39286-cit-0032"><string-name name-style="western"><surname>Marquis&#8208;Gravel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hammill</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Mulder</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Wruck</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Sharlow</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Pohlman</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname><given-names>AF</given-names></string-name>, et&#160;al. <article-title>Validation of cardiovascular end points ascertainment leveraging multisource electronic health records harmonized into a common data model in the adaptable randomized clinical trial</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2021</year>;<volume>14</volume>:<elocation-id>e008190</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.121.008190</pub-id><pub-id pub-id-type="pmid">34886680</pub-id></mixed-citation></ref><ref id="jah39286-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah39286-cit-0033"><string-name name-style="western"><surname>Armstrong</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Kirkby</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Zain</surname><given-names>ZN</given-names></string-name>, <string-name name-style="western"><surname>Emerson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Warner</surname><given-names>TD</given-names></string-name>. <article-title>Thrombosis is reduced by inhibition of COX&#8208;1, but unaffected by inhibition of COX&#8208;2, in an acute model of platelet activation in the mouse</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>:<elocation-id>e20062</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0020062</pub-id><pub-id pub-id-type="pmid">21629780</pub-id><pub-id pub-id-type="pmcid">PMC3100333</pub-id></mixed-citation></ref><ref id="jah39286-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah39286-cit-0034"><string-name name-style="western"><surname>Eikelboom</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Connolly</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Bosch</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dagenais</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Shestakovska</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Alings</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lonn</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Anand</surname><given-names>SS</given-names></string-name>, et&#160;al. <article-title>Rivaroxaban with or without aspirin in stable cardiovascular disease</article-title>. <source>N&#160;Engl J Med</source>. <year>2017</year>;<volume>377</volume>:<fpage>1319</fpage>&#8211;<lpage>1330</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1709118</pub-id><pub-id pub-id-type="pmid">28844192</pub-id></mixed-citation></ref><ref id="jah39286-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah39286-cit-0035"><string-name name-style="western"><surname>Knuuti</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wijns</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Saraste</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Capodanno</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Barbato</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Funck&#8208;Brentano</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Prescott</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Storey</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Deaton</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cuisset</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source>. <year>2019</year>;<volume>41</volume>:<fpage>407</fpage>&#8211;<lpage>477</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehz425</pub-id><pub-id pub-id-type="pmid">31504439</pub-id></mixed-citation></ref><ref id="jah39286-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah39286-cit-0036"><string-name name-style="western"><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Baber</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Briguori</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cha</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Collier</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dangas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dudek</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Ticagrelor with or without aspirin in high&#8208;risk patients after PCI</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>381</volume>:<fpage>2032</fpage>&#8211;<lpage>2042</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1908419</pub-id><pub-id pub-id-type="pmid">31556978</pub-id></mixed-citation></ref><ref id="jah39286-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah39286-cit-0037"><string-name name-style="western"><surname>Kim</surname><given-names>B&#8208;K</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>S&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>Y&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Suh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Her</surname><given-names>A&#8208;Y</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname><given-names>DW</given-names></string-name>, et&#160;al. <article-title>Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>:<fpage>2407</fpage>&#8211;<lpage>2416</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2020.7580</pub-id><pub-id pub-id-type="pmid">32543684</pub-id><pub-id pub-id-type="pmcid">PMC7298605</pub-id></mixed-citation></ref><ref id="jah39286-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah39286-cit-0038"><string-name name-style="western"><surname>Vranckx</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>J&#252;ni</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hamm</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Heg</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>van Es</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>McFadden</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Onuma</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>van Meijeren</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug&#8208;eluting stent: a multicentre, open&#8208;label, randomised superiority trial</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>392</volume>:<fpage>940</fpage>&#8211;<lpage>949</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31858-0</pub-id><pub-id pub-id-type="pmid">30166073</pub-id></mixed-citation></ref><ref id="jah39286-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah39286-cit-0039"><string-name name-style="western"><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Baber</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Sartori</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Dangas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Briguori</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Collier</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Impact of age on the safety and efficacy of ticagrelor monotherapy in patients undergoing PCI</article-title>. <source>J Am Coll Cardiol Intv</source>. <year>2021</year>;<volume>14</volume>:<fpage>1434</fpage>&#8211;<lpage>1446</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2021.04.043</pub-id><pub-id pub-id-type="pmid">34238553</pub-id></mixed-citation></ref><ref id="jah39286-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jah39286-cit-0040"><string-name name-style="western"><surname>Cryer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Lanza</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>J&#8208;f</given-names></string-name>, <string-name name-style="western"><surname>Lichtenberger</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Marathi</surname><given-names>UK</given-names></string-name>. <article-title>Low&#8208;dose aspirin&#8208;induced ulceration is attenuated by aspirin&#8211;phosphatidylcholine: a randomized clinical trial</article-title>. <source>Am J Gastroenterol</source>. <year>2011</year>;<volume>106</volume>:<fpage>272</fpage>&#8211;<lpage>277</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ajg.2010.436</pub-id><pub-id pub-id-type="pmid">21081908</pub-id></mixed-citation></ref><ref id="jah39286-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jah39286-cit-0041"><string-name name-style="western"><surname>Angiolillo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Lanza</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Deliargyris</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Prats</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Marathi</surname><given-names>U</given-names></string-name>. <article-title>Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation</article-title>. <source>J Thromb Thrombolysis</source>. <year>2020</year>;<volume>49</volume>:<fpage>337</fpage>&#8211;<lpage>343</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11239-020-02051-5</pub-id><pub-id pub-id-type="pmid">32080811</pub-id><pub-id pub-id-type="pmcid">PMC7145786</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>